日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies

NA-PHER2 试验中接受 HER2 靶向和内分泌治疗的 HER2+ER+ 乳腺癌的疗效和分子动力学决定因素

Maurizio Callari, Matteo Dugo, Marco Barreca, Balázs Győrffy, Barbara Galbardi, Lucia Vigano, Alberta Locatelli, Chiara Dall'Ara, Marina Ferrarini, Giancarlo Bisagni, Marco Colleoni, Mauro Mansutti, Claudio Zamagni, Lucia Del Mastro, Stefania Zambelli, Antonio Frassoldati, Olivia Biasi, Lajos Puszta

Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor- and ErbB2-positive Breast Cancer

CDK4/6 抑制调节雌激素/erbB2 受体串扰可引发雌激素受体和 ErbB2 阳性乳腺癌的持续衰老

Lucia Viganò #, Alberta Locatelli #, Adele Ulisse, Barbara Galbardi, Matteo Dugo, Diego Tosi, Carlo Tacchetti, Tiziana Daniele, Balázs Győrffy, Lorenzo Sica, Marina Macchini, Milvia Zambetti, Stefania Zambelli, Giampaolo Bianchini, Luca Gianni

Direct stimulation of ERBB2 highlights a novel cytostatic signaling pathway driven by the receptor Thr701 phosphorylation

ERBB2 的直接刺激凸显了由受体 Thr701 磷酸化驱动的新型细胞抑制信号通路

Marco Gaviraghi #, Andrea Rabellino #, Annapaola Andolfo, Matthias Brand, Chiara Brombin, Paola Bagnato, Giuseppina De Feudis, Andrea Raimondi, Alberta Locatelli, Daniela Tosoni, Davide Mazza, Luca Gianni, Giovanni Tonon, Yosef Yarden, Carlo Tacchetti, Tiziana Daniele5